|
|
|
| Bhupesh Bhandari: The new pharmaceutical order | 23-OCT-09 |
|
| The original poster boys of the Indian pharmaceutical industry all seem to be in a spot of bother. Habil Khorakiwala of Wockhardt has sold his animal health, nutrition and hospital businesses to repay the debt on his books. Dilip Shanhgvi of Sun Pharma faces regulatory problems in the US. Caraco Pharmaceuticals, a company he owns in that country, faces a manufacturing ban imposed by the Food & Drug Administration. Dr Reddy’s Laboratories has had to recall products in the US. |
|
|
|
| Caraco agrees to undertake action to get USFDA ban lifted | 01-OCT-09 |
|
| Sun Pharma's US-based subsidiary Caraco Pharmaceuticals has agreed to undertake a series of measures as per requirements of the US health regulator Food and Drug Administration (FDA) to get a ban on its manufacturing units lifted. |
|
|
|
| Sun, Caraco to file 30 marketing applications for generics | 17-SEP-09 |
|
| Sun Pharmaceutical Industries and its troubled US subsidiary, Caraco Pharmaceuticals, plan to together file 30 Abbreviated New Drug Applications with the US Food and Drug Administration (FDA) to market generic drugs, despite regulatory issues for the US company. |
|
|
|
| Sun Pharma ends flat on Caraco worries | 21-AUG-09 |
|
| Sun Pharma finally ended marginally down at Rs 1,184. The counter saw trades of around 38,000 shares as against its two-week average trades of 31,295 shares. |
|
|
|
| Turnaround at operating level for pharma sector | 10-AUG-09 |
|
| Pharmaceuticals companies struggled for volume growth during the quarter ended June due to weak US markets, but still ended with profit before tax and extraordinary income of Rs 2,502 crore compared to a net loss during the preceding two quarters. |
|
|
|
| Sun Pharma uses own plants for US market after after Caraco trouble | 02-AUG-09 |
|
| In spite of a major regulatory clampdown on its US subsidiary, Caraco, Mumbai-based Sun Pharmaceuticals is trying hard to keep its US market share intact. The company is relying on its own manufacturing facilities to deliver goods to the US market. All eight ANDAs (abbreviated new drug applications) for sales permission in the US filed during the first quarter of the current financial year (Q1FY2010) came from Sun’s facilities. |
|
|
|
| The Caraco headache | 13-JUL-09 |
|
| The seizure of Caraco’s drugs by the FDA could have an adverse impact on Sun Pharmaceutical in the near term. |
|
|
|
| Sun Pharma, Forest settle US suit on Lexapro | 11-JUL-09 |
|
| Sun Pharmaceutical Industries and its subsidiary, Caraco Pharmaceutical Laboratories, have reached a settlement agreement with drugmaker Forest Laboratories and licensing partner H Lundbeck AS, over a pending patent infringement dispute over Forest’s blockbuster antidepressant, Lexapro. |
|
|
|
| Sun Pharma: Inclement weather | 30-JUN-09 |
|
| Sun Pharma continues to face rough weather in the US markets. Loss of production at three Michigan units of its subsidiary, Caraco, as a result of the US FDA’s action, could hit the company’s profit before tax by 10-15 per cent, analysts estimate. |
|
|
|
| Caraco shock: Sun Pharma to revise guidance | 28-JUN-09 |
|
| Sun Pharma today said it would revise the revenue guidance for 2009-10 as the company was not sure when its US subsidiary, Caraco Pharmaceuticals, would be able to meet the regulatory standards of the Food and Drug Administration (USFDA). |
|
|
|
|
|
|
|
|
|
| Sun Pharma crashes on Caraco ruling | 26-JUN-09 |
|
| Sun Pharma recovered partially from the day's low of Rs 1,070, and finally ended 12% lower at Rs 1,140. The counter registered heavy volumes of around 580,400 shares, which is around 30-times higher than its two-week daily average volume of around 19,230 shares on the BSE. |
|
|
|
| UPDATE: FDA seizes Caraco drugs over norms violation | 26-JUN-09 |
|
| In a major setback to Sun Pharmaceutical Industries - the largest Indian drug maker in terms of market capitalisation, the US Food and Drug Administration (FDA) has seized all medicines produced by Sun’s US arm Caraco Pharmaceutical Laboratories, for repeated violations of manufacturing standards. |
|
|
|
Content Guide
